PUBLICATIONS & PRESENTATIONS

October 27, 2015

Pulmonary Nontuberculous Mycobacteria Infections: Healthcare Resource Utilization and Costs in Medicare Patients at a US Health Plan
Academy of Managed Care Pharmacy (AMCP) Nexus 2015 Conference
Download PDF

October 8, 2015

Pulmonary Nontuberculous Mycobacteria Infections: Pre-Index Comorbidity and Utilization Patterns at a Large US Health Plan
Infectious Disease Week 2015
Download PDF

October 8, 2015

Pharmacokinetic Profile of Liposomal Amikacin for Inhalation in Patients with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Infection
North American Cystic Fibrosis Conference
Download PDF

October 8, 2015

Long-Term Study of Liposomal Amikacin for Inhalation in Patients with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Infection
North American Cystic Fibrosis Conference
Download PDF

September 29, 2015

A randomized, open-label, multicenter study of liposomal amikacin for inhalation in adult patients with nontuberculous mycobacteria (NTM) lung infections caused by mycobacterium avium complex (MAC)
European Respiratory Society International Congress
Download PDF

September 27, 2015

Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI)
European Respiratory Society International Congress
Download PDF

September 19, 2015

Nontuberculous Mycobacteria Lung Infections: Increasing Incidence of Diagnosis in Medicare Patients at a US Health Plan
Interscience Conference of Antimicrobial Agents and Chemotherapy
Download PDF

September 18, 2015

Pharmacokinetic (PK) Evaluation of Liposomal Amikacin for Inhalation (LAI) in Patients with Treatment-refractory Nontuberculous Mycobacteria (NTM) Lung Infection Interscience Conference of Antimicrobial Agents and Chemotherapy
Download PDF

May 20, 2015

Analysis of Functional Exercise Capacity (via the Six-Minute Walk Test [6MWT]) and Negative Sputum Culture for NTM in Patients With NTM Lung Infection Refractory to Guideline-Based Therapy Treated With Liposomal Amikacin for Inhalation
American Thoracic Society International Conference
Download PDF

May 20, 2015

Efficacy of Liposomal Amikacin for Inhalation in Achieving Negative Sputum Cultures for Nontuberculous Mycobacteria in Patients Whose Lung Infection Is Refractory to Guideline-Based Therapy
American Thoracic Society International Conference
Download PDF

May 20, 2015

Subgroup Analyses of Baseline Demographics and Efficacy in Patients With Refractory Nontuberculous Mycobacteria (NTM) Lung Infection Treated With Liposomal Amikacin for Inhalation (LAI)
American Thoracic Society International Conference
Download PDF

May 17, 2015

A 14-Day Assessment of the Tolerability and Pharmacokinetics of a Nanoparticle Formulation of Hexadecyl-Treprostinil, a Long-Acting
Pulmonary Vasodilator, in Rats
American Thoracic Society International Conference
Download PDF

May 17, 2015

Pharmacokinetic Profile of a Prodrug Lipid Nanoparticle Formulation of Treprostinil in Dogs
American Thoracic Society International Conference
Download PDF

May 17, 2015

Effect of a Lipid Nanoparticle Prodrug Formulation of Treprostinil (INS1009) on the Cough Reflex in Guinea Pigs
American Thoracic Society International Conference
Download PDF

October 9, 2014

Lung Distribution and Clearance of Low- or High-Dose Dual-Labeled Liposomal Amikacin for Inhalation in Rats Dosed Once Daily for 28 Days
2014 North American Cystic Fibrosis Conference
Download PDF

October 9, 2014

Analysis of Long-Term Liposomal Amikacin for Inhalation in Patients With Cystic Fibrosis and Chronic Infection From Pseudomonas aeruginosa
2014 North American Cystic Fibrosis Conference
Download PDF

October 9, 2014

Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension of Liposomal Amikacin for Inhalation (LAI) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease (NTM-LD)
2014 North American Cystic Fibrosis Conference
Download PDF

September 8, 2014

Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension
Thematic Poster Session: Pulmonary hypertension: novel targets and drugs
Download PDF

September 8, 2014

Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells
Thematic Poster Session: Pulmonary hypertension: novel targets and drugs
Download PDF

September 8, 2014

Prolonged activity of inhaled treprostinil prodrug-nanoparticles in a rat model of pulmonary arterial hypertension
Thematic Poster Session: Pulmonary hypertension: novel targets and drugs
Download PDF

September 8, 2014

Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations
Thematic Poster Session: Pulmonary hypertension: novel targets and drugs
Download PDF

September 7, 2014

Comparison of treatment practices for nontuberculous mycobacterial pulmonary disease in Japan, Europe and United States
Thematic Poster Session: The epidemiology of respiratory infections and lung cancer
Download PDF

September 7, 2014

Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative study
Thematic Poster Session: The epidemiology of respiratory infections and lung cancer
Download PDF

May 20, 2014

A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease
American Thoracic Society’s International Conference 2014
Download PDF

May 20, 2014

Clinical Benefit of Liposomal Amikacin for Inhalation as Assessed by the Cystic Fibrosis Questionnaire-Revised
American Thoracic Society’s International Conference 2014
Download PDF

May 18, 2014

Interim Analysis from Two-Year, Open Label Extension Study of Arikayce to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
American Thoracic Society’s International Conference 2014
Download PDF

October 17, 2013

Phase 3 Efficacy and Safety Data from Randomized, Multicenter Study of Liposomal Amikacin for Inhalation
2013 North American Cystic Fibrosis Conference (NACFC)
Download PDF

Phase 2 study of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
JP Clancy, L Dupont, MW Konstan, J Billings, S Fustik, CH Goss, J Lymp, P Minic, AL Quittner, RC Rubenstein, KR Young, L Saiman, JL Burns, J R W Govan, B Ramsey, R Gupta, for the Arikace Study Group. Thorax 2013;68:818-825.
View Publication

June 10, 2011

A multi-cycle open-label study of nebulized liposomal amikacin (ARIKACE) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
34th European Cystic Fibrosis Society (ECFS) Conference Poster #217 Presentation
Download PDF

June 10, 2011

A multi-cycle open-label study of nebulized liposomal amikacin (ARIKACE) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
34th European Cystic Fibrosis Society (ECFS) Conference Poster #217 Presentation
Download PDF

October 21, 2010

A multi-cycle open-label study of nebulized liposomal amikacin (ARIKACE) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
24th Annual North American Cystic Fibrosis Conference Poster #243
Download PDF

October 21, 2010

Full analyses of data from two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin for inhalation (ARIKACE) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
24th Annual North American Cystic Fibrosis Conference Poster #227
Download PDF

June 17, 2010

A multi-cycle open-label study of nebulized liposomal amikacin (ARIKACE) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
33rd European Cystic Fibrosis Society (ECFS) Conference Oral Presentation
Download PDF

June 17, 2010

A multi-cycle open-label study of nebulized liposomal amikacin (ARIKACE) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
33rd European Cystic Fibrosis Society (ECFS) Conference Poster #236
Download PDF

May 16, 2010

Evaluation of two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin (ARIKACE) in the treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infection
International Conference of the American Thoracic Society Poster #1836
Download PDF

October 15, 2009

ARIKACE-Liposomal Amikacin: Preclinical Summary
23rd Annual North American Cystic Fibrosis Conference
Download PDF

September 13, 2009

A placebo controlled, randomized, parallel cohort, safety and tolerability study of two dose levels of liposomal amikacin for inhalation (ARIKACE) in patients with bronchiectasis complicated by chronic infection due to Pseudomonas aeruginosa
European Respiratory Society Annual Congress 2009
Download PDF

September, 2009

Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 2009
View Publication